• Home
  • NEW DAY MEDICINE
  • 1 (87) 2026
  • 4 -1 (87) 2026 - Djabbarova N.M. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

4 -1 (87) 2026 - Djabbarova N.M. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

Djabbarova N.M. - Samarkand State Medical University

Resume

The development of non-alcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes mellitus in obese patients is of great importance in choosing treatment tactics, treatment duration, and the occurrence of uncertain outcomes in the development of NAFLD. In our study, to assess the effectiveness of SGLT2 inhibitors in patients with NAFLD against the background of insulin resistance, we used dapagliflozin at a dose of 10 mg for 6 months in 62 patients aged 20-65 years with non-alcoholic fatty liver disease during ultrasound examination. All patients underwent biochemical and anthropometric studies, bioimpedance measurement, abdominal ultrasound before and after treatment, and a comparative analysis. The results showed that during therapy with dapagliflozin in NAFLD, biochemical parameters, insulin sensitivity, lipid profile, body component composition, and weight loss significantly improved.

Keywords: Non-alcoholic fatty liver disease, steatosis, Dapagliflozin, SGLT2 inhibitors

First page

22

Last page

26

For citation:Djabbarova N.M. - SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE//New Day in Medicine 1(87)2026 22-26 https://newdayworldmedicine.com/en/new_day_medicine/1-87-2026

List of References

  1. Younossi Z.M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. // Hepatology (Baltimore, Md.), 2023;77(4):1335–1347. https://doi.org/10.1097/HEP.0000000000000004
  2. N.M. Jabbarova, I.R. Agababyan Effectiveness of type 2 sodium-glucose cotransporter inhibitors in patients with nonalcoholic fatty liver disease against the background of insulin resistance. // Journal of cardiorespiratory research. 2025;6(2/4):10-19.
  3. Agababyan R. Irina, Djabbarova M. Nafisa. Current issues in modern treatment of nonalcoholic fatty liver disease // Journal of Biomedicine and Practice. 2024;9(2).
  4. Агабабян Ирина Рубеновна, Джаббарова Нафиса Мамасолиевна, Рофеев Мумин Шамсиевич, Назарова Зухра Шариповна, Пулатова Кристина Самвеловна (2019). Метаболический синдром как один из основных факторов развития артериальной гипертонии. // Достижения науки и образования, 2019;10(51):54-58.
  5. Targher, G., Tilg, H., Byrne, C. D. (2021). Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. // The lancet. Gastroenterology hepatology, 2021;6(7):578–588. https://doi.org/10.1016/S2468-1253(21)00020-0
  6. Tobita H., Sato, S., Miyake, T., Ishihara, S., & Kinoshita, Y. (2017). Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. // Current therapeutic research, clinical and experimental, 2017;87:13–19. https://doi.org/10.1016/j.curtheres.2017.07.002
  7. Gameil, M.A., Abdelgawad, M.S., Bahgat, M.H. et al. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. // Egypt J Intern Med 32, 12 (2020). https://doi.org/10.1186/s43162-020-00013-0
  8. Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., & Aso, Y. (2019). Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. // Diabetes, obesity metabolism, 2019;21(2):285–292. https://doi.org/10.1111/dom.13520
  9. Sattar, N., Fitchett, D., Hantel, S., George, J. T., Zinman, B. (2018). Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. // Diabetologia, 2018;61(10):2155–2163. https://doi.org/10.1007/s00125-018-4702-3
  10. Eriksson J. W., Lundkvist, P., Jansson, P. A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G. B., Risérus, U., Lind, L., Oscarsson, J. (2018). Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. // Diabetologia 2018;61(9):1923–1934. https://doi.org/10.1007/s00125-018-4675-2

    file

    download